TY - JOUR T1 - Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis JF - medRxiv DO - 10.1101/2020.11.03.20224998 SP - 2020.11.03.20224998 AU - Ping Yuan AU - Pu Ai AU - Yihan Liu AU - Zisheng Ai AU - Yi Wang AU - Weijun Cao AU - Xiaohuan Xia AU - Jialin C. Zheng Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/04/2020.11.03.20224998.abstract N2 - We aimed to summarize reliable medical evidence by the meta-analysis of all published clinical trials that investigated the safety, tolerability, and immunogenicity of vaccine candidates against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The PubMed, Cochrane Library, EMBASE, and medRxiv databases were used to select the studies. 7094 articles were identified initially and 43 were retrieved for more detailed evaluation. 5 randomized, double-blind, placebo-controlled trials were selected. A total of 1604 subjects with either vaccines or placebo infections were included in the meta-analysis within the scope of these articles. According to the results, there is an increase in total adverse events for subjects with either low (95% CI: 1.90-4.29) or high (CI: 2.65-5.63) dose vaccination. The adverse effects of COVID-19 vaccine are mainly local ones including pain, itching, and redness, and no significant difference was identified in the systemic reactions. All adverse effects were transient and resolved within a few days. Moreover, the neutralizing and IgG antibody levels post different dose vaccinations were all significantly increased at day 14/21 (P = 0.0004 and P = 0.0003, respectively) and day 28/35 (P < 0.00001) in vaccine groups compared to placebo controls. Besides, the levels of neutralizing and IgG antibodies were also elevated significantly at from day 14 to 35, versus day 0 (All P < 0.001). In conclusion, our analysis suggests that the current COVID-19 vaccine candidates are safe, tolerated, and immunogenic, which provides important information for further development, evaluation, and clinical application of COVID-19 vaccine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by research grants from the Major Research plan of the National Natural Science Foundation of China (No. 91949204 to J.C.Z.), the State Key Program of the National Natural Science Foundation of China (No. 81830037 to J.C.Z.), the National Basic Research Program of China (973 Program Grant No. 2014CB965001 to J.C.Z.), the National Institutes of Health (1R01NS097195-01 to J.C.Z.), the National Natural Science Foundation of China (No. 81901333 to X.X.), and Shanghai Sailing Program (No. 19YF1451700 to X.X.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The manuscript is a meta-analysis that does not require approval of the IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll datasets generated for this study are included in the manuscript. ER -